|
KMID : 0043320210440010117
|
|
Archives of Pharmacal Research
2021 Volume.44 No. 1 p.117 ~ p.132
|
|
|
IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn’s disease and new therapeutic targets
|
|
Idrissi Doha Anka
Senhaji Nezha
Aouiss Asmae
Khalki Loubna
Tijani Youssef
Zaid Nabil
Marhoume Fatima Zahra
Naya Abdallah
Oudghiri Mounia
Kabine Mostafa
Zaid Younes
|
|
|
Abstract
|
|
|
|
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic and multifactorial diseases that affect the intestinal tract, both characterized by recurrent inflammation of the intestinal mucosa, resulting in abdominal pain, diarrhea, vomiting and, rectal bleeding. Inflammatory bowel diseases (IBD) regroup these two disorders. The exact pathological mechanism of IBD remains ambiguous and poorly known. In genetically predisposed patients, defects in intestinal mucosal barrier are due to an uncontrolled inflammatory response to normal flora. In addition to the genetic predisposition, these defects could be triggered by environmental factors or by a specific lifestyle which is widely accepted as etiological hypothesis. The involvement of the CD40/CD40L platelet complex in the development of IBD has been overwhelmingly demonstrated. CD40L is climacteric in cell signalling in innate and adaptive immunity, the CD40L expression on the platelet cell surface gives them an immunological competence. The IL-1, a major inflammation mediator could be involved in different ways in the development of IBD. Here, we provide a comprehensive review regarding the role of platelet CD40/CD40L in the pathophysiological effect of IL-1 in the development of Crohn’s disease (CD). This review could potentially help future approaches aiming to target these two pathways for therapeutic purposes and elucidate the immunological mechanisms driving gut inflammation.
|
|
|
KEYWORD
|
|
|
Crohn's disease, IBD, CD40/CD40L axis, IL-1, Inflammation, Autoimmunity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|